Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 22.
Article
Abubakar, I;
Kloprogge, F;
(2017)
End of the Road for Adjunctive Vitamin D Therapy for Pulmonary Tuberculosis?
American Journal of Respiratory and Critical Care Medicine
, 196
(5)
pp. 544-545.
10.1164/rccm.201707-1509ED.
|
|
Boonsathorn, S;
Cheng, I;
Kloprogge, F;
Alonso, C;
Lee, C;
Doncheva, B;
Booth, J;
... Standing, JF; + view all
(2019)
Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.
Clinical Pharmacokinetics
, 58
(1)
pp. 53-61.
10.1007/s40262-018-0658-1.
|
 |
|
Carrara, L;
Magni, P;
Teutonico, D;
Pasotti, L;
Pasqua, OD;
Kloprogge, F;
(2020)
Ethambutol disposition in humans: challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development.
European Journal of Pharmaceutical Sciences
, 150
, Article 105359. 10.1016/j.ejps.2020.105359.
|
|
Chiesa, R;
Standing, JF;
Winter, R;
Nademi, Z;
Chu, J;
Pinner, D;
Kloprogge, F;
... Slatter, M; + view all
(2019)
Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial.
Clinical Pharmacology & Therapeutics
10.1002/cpt.1715.
(In press).
|
|
|
Gastine, S;
Pang, J;
Boshier, FAT;
Carter, SJ;
Lonsdale, DO;
Cortina-Borja, M;
Hung, IFN;
... Standing, JF; + view all
(2021)
Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies.
Clinical Pharmacology and Therapeutics
, 110
(2)
pp. 321-333.
10.1002/cpt.2223.
|
|
|
Gonzalez Hernandez, F;
Carter, SJ;
Iso-Sipilä, J;
Goldsmith, P;
Almousa, AA;
Gastine, S;
Lilaonitkul, W;
... Standing, JF; + view all
(2021)
An automated approach to identify scientific publications reporting pharmacokinetic parameters [version 1; peer review: awaiting peer review].
Wellcome Open Research
, 6
, Article 88. 10.12688/wellcomeopenres.16718.1.
|
|
|
Huang, Zhonghui;
Denti, Paolo;
Mistry, Hitesh;
Kloprogge, Frank;
(2024)
Machine Learning and Artificial Intelligence in PK-PD Modeling: Fad, Friend, or Foe?
Clinical Pharmacology & Therapeutics
10.1002/cpt.3165.
(In press).
|
|
Kloprogge, F;
Ortiz Canseco, J;
Phee, L;
Sadouki, Z;
Kipper, K;
Witney, AA;
Stoker, N;
(2022)
Emergence of phenotypic and genotypic antimicrobial resistance in Mycobacterium tuberculosis.
Scientific Reports
, 12
, Article 21429. 10.1038/s41598-022-25827-6.
|
|
Kloprogge, F;
Abubakar, I;
Esmail, H;
Hack, V;
Kunst, H;
McHugh, TD;
Noursadeghi, M;
... Lipman, M; + view all
(2021)
Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study.
BMJ Open
, 11
(7)
, Article e052885. 10.1136/bmjopen-2021-052885.
|
|
|
Kloprogge, F;
Hammond, R;
Copas, A;
Gillespie, SH;
Della Pasqua, O;
(2019)
Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?
Journal of Antimicrobial Chemotherapy
, 74
(12)
pp. 3530-3536.
10.1093/jac/dkz369.
(In press).
|
|
|
Kloprogge, F;
Hammond, R;
Kipper, K;
Gillespie, SH;
Della Pasqua, O;
(2019)
Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection.
Scientific Reports
, 9
, Article 13228. 10.1038/s41598-019-49556-5.
|
|
|
Kloprogge, F;
Hill, LF;
Booth, J;
Klein, N;
Irwin, A;
Dixon, G;
Standing, JF;
(2019)
Revising paediatric vancomycin dosing accounting for nephrotoxicity in a pharmacokinetic-pharmacodynamic model.
Antimicrobial Agents and Chemotherapy
10.1128/AAC.00067-19.
(In press).
|
|
|
Kloprogge, F;
McGready, R;
Hanpithakpong, W;
Blessborn, D;
Day, NP;
White, NJ;
Nosten, F;
(2015)
Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.
Antimicrobial Agents and Chemotherapy
, 59
(10)
pp. 6375-6384.
10.1128/AAC.00267-15.
|
|
|
Kloprogge, F;
Mwandumba, HC;
Banda, G;
Kamdolozi, M;
Shani, D;
Corbett, EL;
Kontogianni, N;
... Sloan, DJ; + view all
(2020)
Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis.
Open Forum Infectious Diseases
, 7
(7)
, Article ofaa218. 10.1093/ofid/ofaa218.
|
|
|
Kloprogge, F;
Workman, L;
Borrmann, S;
Tékété, M;
Lefèvre, G;
Hamed, K;
Piola, P;
... Tarning, J; + view all
(2018)
Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
PLoS Medicine
, 15
(6)
, Article e1002579. 10.1371/journal.pmed.1002579.
|
|
Maitra, A;
Solanki, P;
Sadouki, Z;
McHugh, TD;
Kloprogge, F;
(2021)
Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model.
Antibiotics
, 10
(12)
, Article 1515. 10.3390/antibiotics10121515.
|
|
|
Nyang'wa, B-T;
Kloprogge, F;
Moore, DAJ;
Bustinduy, A;
Motta, I;
Berry, C;
Davies, GR;
(2021)
Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial.
BMJ Open
, 11
(9)
, Article e047185. 10.1136/bmjopen-2020-047185.
|
|
|
Parasuraman, JM;
Kloprogge, F;
Standing, JF;
Albur, M;
Heep, A;
(2020)
Population Pharmacokinetics of Intraventricular Vancomycin in Neonatal Ventriculitis, A Preterm Pilot Study.
European Journal of Pharmaceutical Sciences
, Article 105643. 10.1016/j.ejps.2020.105643.
(In press).
|
|
|
Phee, LM;
Kloprogge, F;
Morris, R;
Barrett, J;
Wareham, DW;
Standing, JF;
(2019)
Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii.
Journal of Antimicrobial Chemotherapy
, 74
(4)
, Article dky524. 10.1093/jac/dky524.
|
|
|
Sadouki, Z;
McHugh, TD;
Aarnoutse, R;
Ortiz Canseco, J;
Darlow, C;
Hope, W;
van Ingen, J;
... Kloprogge, F; + view all
(2021)
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting.
Journal of Antimicrobial Chemotherapy
10.1093/jac/dkab160.
(In press).
|
|
|
Scarpa, M;
Paudel, A;
Kloprogge, F;
Kai Hsiao, W;
Bresciani, M;
Gaisford, S;
Orlu, M;
(2018)
Key acceptability attributes of orodispersible films.
European Journal of Pharmaceutics and Biopharmaceutics
, 125
pp. 131-140.
10.1016/j.ejpb.2018.01.003.
|
|
Wijk, Marie;
Denti, Paolo;
Gausi, Kamunkhwala;
Myers, Bronwyn;
Carney, Tara;
White, Laura F;
Theron, Danie;
... Kloprogge, Frank; + view all
(2025)
Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment.
Clinical Infectious Diseases
, Article ciaf586. 10.1093/cid/ciaf586.
(In press).
|
|
